SCHEMBL3015258

SCHEMBL3015258

Cc1cccc(-c2csc(N3CCN(S(=O)(=O)c4cccc(Br)c4)CC3)n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
USP2 O75604 5/20 0.57
HSD17B10 Q99714 3/20 0.57
RECQL P46063 1/20 0.57
NPSR1 Q6W5P4 1/20 0.54
LMNA P02545 6/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
MAPK1 P28482 2/20 0.53
ALDH1A1 P00352 9/20 0.53
GAA P10253 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HPGD P15428 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ALOX15 P16050 1/20 0.53
HTT P42858 2/20 0.52
KDM4E B2RXH2 1/20 0.52
HIF1A Q16665 1/20 0.47
PTPN1 P18031 1/20 0.45
PTPN6 P29350 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008690 0.93 ALDH1A1 (0.53) MAPTUSP2HSD17B10RECQLNPSR1
SCHEMBL3010391 0.93 MAPT (0.59) MAPTUSP2HSD17B10RECQLNPSR1
SCHEMBL3014041 0.91 ALDH1A1 (0.59) MAPTUSP2HSD17B10RECQLNPSR1
SCHEMBL3015952 0.91 MAPT (0.63) MAPTUSP2HSD17B10RECQLNPSR1
SCHEMBL3004740 0.90 LMNA (0.63) MAPTUSP2HSD17B10RECQLNPSR1
SCHEMBL3014854 0.89 ALDH1A1 (0.54) MAPTUSP2HSD17B10RECQLNPSR1
SCHEMBL3016137 0.89 MAPT (0.63) MAPTUSP2HSD17B10RECQLNPSR1
SCHEMBL3010816 0.88 MAPT (0.57) MAPTUSP2HSD17B10RECQLNPSR1
SCHEMBL2999057 0.88 MAPT (0.65) MAPTUSP2HSD17B10RECQLNPSR1
SCHEMBL3011171 0.88 MAPT (0.66) MAPTUSP2HSD17B10RECQLNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.